An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

第五届单细胞与空间组学论坛近日，中山大学/湖南省人民医院研究团队合作共同在期刊《Science Advances》上发表了研究论文，题为“Lactate derived from cancer-associated fibroblasts ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

CLEVELAND – Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The study involved ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...